screen
rna
mutagen
resist
isol
high
fidel
rna
depend
rna
polymeras
rdrp
variant
coxsacki
viru
curious
variant
also
resist
amilorid
hypothes
amilorid
previous
undescrib
mutagen
activ
inde
amilorid
compound
increas
mutat
frequenc
polioviru
high
fidel
variant
virus
resist
effect
hypothes
mutagen
activ
mediat
alter
intracellular
ion
mg
mn
turn
increas
viru
mutat
frequenc
affect
rdrp
fidel
furthermor
show
anoth
amilorideresist
rdrp
variant
complet
resist
mutagen
activ
unaffect
chang
ion
concentr
show
rdrp
variant
resist
mutagen
activ
amilorid
via
two
differ
mechan
increas
fidel
gener
viru
popul
present
lower
basal
mutat
frequenc
resist
chang
dival
cation
concentr
affect
polymeras
fidel
result
uncov
new
antivir
approach
base
mutagenesi
amilorid
deriv
potassiumspar
diuret
use
treat
hypertens
prevent
hypokalemia
associ
congest
heart
failur
compound
act
inhibit
epitheli
na
channel
na
h
na
ca
na
mg
antiport
function
due
rel
low
toxic
antivir
properti
amilorid
explor
compound
inhibit
viroporin
coronavirus
flavivirus
retrovirus
recent
amilorid
shown
exert
antivir
effect
rhinoviru
common
cold
coxsacki
viru
viral
myocard
directli
affect
viru
replic
releas
studi
harrison
et
al
isol
two
viral
rna
depend
rna
polymeras
rdrp
mutant
resist
amilorid
wild
type
viru
mechan
resist
remain
unclear
isol
one
rdrp
mutant
screen
resist
rna
mutagen
goal
identifi
higher
fidel
rdrp
variant
rna
mutagen
ribavirin
base
analog
incorrectli
insert
genom
rdrp
replic
result
accumul
lethal
mutat
sever
passag
process
refer
lethal
mutagenesi
similar
screen
previous
identifi
higher
fidel
variant
polioviru
suggest
intrins
fidel
rdrp
modul
despit
lack
proofread
function
polioviru
rdrp
fidel
variant
sinc
proven
use
tool
studi
role
genet
divers
viru
fit
virul
shown
promis
improv
vaccin
attenu
genet
stabil
order
extend
observ
medic
relev
virus
perform
screen
high
fidel
variant
select
resist
mutagen
base
analog
ribavirin
identifi
variant
higher
fidel
map
differ
region
rdrp
previous
describ
posit
polioviru
sinc
mutat
confer
resist
rna
mutagen
amilorid
hypothes
amilorid
previous
unknown
mutagen
activ
report
provid
first
evid
indirect
rna
mutagen
activ
amilorid
compound
show
amilorid
resist
rdrp
variant
resist
mutagen
activ
two
differ
mechan
determin
condit
gener
resist
rna
mutagen
treat
variou
concentr
ribavirin
azc
mutagen
concentr
mm
decreas
viral
viabil
figur
order
exert
strong
enough
select
pressur
without
extinguish
viru
popul
passag
serial
passag
larg
viru
popul
size
tcid
mm
either
mutagen
everi
five
passag
viral
rnadepend
rna
polymeras
rdrp
region
sequenc
figur
wild
type
acquir
new
ctou
mutat
result
alanin
valin
chang
posit
rdrp
passag
ribavirin
passag
azc
passag
aris
untreat
control
passag
earlier
emerg
mutat
ribavirin
treatment
correl
ribavirin
bia
toward
gtoa
ctou
transit
mutat
compar
azc
bia
ctog
gtoc
transvers
role
resist
confirm
introduc
mutat
back
wild
type
cdna
infecti
clone
compar
growth
wild
type
viru
treat
rna
mutagen
differ
nucleotid
structur
ribavirin
mm
azc
mm
fu
mm
inde
resist
wild
type
viru
case
figur
similar
profil
broad
resist
differ
base
analog
previous
observ
polioviru
high
fidel
variant
suggest
also
higher
fidel
rdrp
confirm
genet
data
wild
type
viru
stock
prepar
infecti
clone
use
infect
cell
treat
mm
ribavirin
mock
treat
total
cytopath
effect
hour
infect
mutat
frequenc
distribut
within
popul
determin
sequenc
kb
fragment
capsid
region
individu
genom
figur
untreat
wild
type
viru
popul
present
mutat
frequenc
mutat
per
nucleotid
figur
tabl
popul
hand
present
mutat
frequenc
approxim
lower
wild
type
p
therebi
confirm
higher
fidel
variant
expect
treatment
mm
ribavirin
significantli
increas
mutat
frequenc
viru
popul
howev
mutat
frequenc
remain
lower
wild
type
p
furthermor
individu
clone
wild
type
viru
popul
often
present
multipl
mutat
compar
tabl
result
confirm
increas
fidel
rdrp
provid
evid
increas
fidel
rdrp
vitro
biochem
assay
use
examin
rel
level
misincorpor
wild
type
enzym
briefli
vitro
reaction
perform
use
equal
amount
purifi
rdrp
satur
concentr
nucleotid
radiolabel
rna
primertempl
substrat
permit
nucleotid
addit
monitor
extens
endlabel
primer
figur
ad
gtp
reaction
incorrect
incorpor
nucleotid
monitor
time
accumul
product
observ
figur
c
rdrp
consist
incorpor
less
gmp
time
wild
type
rdrp
interestingli
observ
rate
correct
nucleotid
incorpor
wild
type
show
signific
differ
wherea
observ
rate
gmp
misincorpor
show
differ
wild
type
rdrp
tabl
confirm
increas
fidel
enzym
dual
resist
rna
mutagen
amilorid
product
increas
replic
capac
curious
previous
isol
screen
resist
amilorid
compound
known
mutagen
activ
shown
reduc
titer
partial
inhibit
rna
synthesi
accordingli
consist
replic
higher
titer
wild
type
concentr
amilorid
test
figur
possibl
explan
dual
resist
rna
mutagen
amilorid
produc
rna
genom
presenc
compound
would
thu
titer
higher
wild
type
determin
whether
higher
titer
presenc
amilorid
due
increas
replic
capac
onestep
growth
analysi
perform
presenc
absenc
amilorid
signific
differ
viru
product
kinet
observ
wild
type
grown
absenc
amilorid
figur
indic
increas
fidel
rdrp
significantli
impact
viru
multipl
furthermor
rna
synthesi
wild
type
similar
kinet
within
order
magnitud
determin
northern
blot
analysi
figur
fact
viru
produc
slightli
less
rna
wild
type
yet
consist
titer
slightli
higher
rna
genom
made
contain
fewer
deleteri
mutat
importantli
differ
observ
wild
type
onestep
growth
kinet
presenc
mm
amilorid
statist
signific
except
one
time
point
hour
p
figur
northern
blot
analysi
reveal
virus
similarli
inhibit
rna
synthesi
figur
heighten
replic
capac
thu
respons
resist
amilorid
sinc
unlik
mutat
confer
resist
two
unrel
antivir
mechan
explor
whether
amilorid
previous
unknown
mutagen
activ
possibl
evid
sinc
amilorid
base
analog
ribavirin
azc
fu
whose
mutagen
effect
result
direct
misincorpor
genom
errorpron
rdrp
hypothes
addit
inhibit
rna
replic
amilorid
compound
increas
viru
mutat
author
summari
rna
virus
extrem
mutat
frequenc
due
larg
part
erron
natur
viral
rna
depend
rna
polymeras
rdrp
replic
genom
sinc
rdrp
lack
proofread
repair
mechan
use
base
analog
rna
mutagen
increas
lethal
mutat
extinguish
viru
popul
promis
antivir
strategi
recent
screen
resist
antivir
treatment
identifi
higher
fidel
rdrp
variant
polioviru
indic
rdrp
fidel
modul
singl
amino
acid
substitut
extend
observ
virus
perform
similar
screen
use
coxsacki
viru
identifi
new
high
fidel
rdrp
variant
also
resist
amilorid
compound
known
mutagen
activ
use
wild
type
rdrp
fidel
variant
polioviru
show
amilorid
compound
mutagen
activ
act
rna
viru
popul
indirectli
alter
intracellular
ion
concentr
affect
polymeras
fidel
result
identifi
new
mean
target
virus
increas
mutat
frequenc
use
nonnucleosid
compound
alter
cellular
environ
viru
replic
frequenc
rna
genom
replic
address
wild
type
viru
infect
perform
presenc
either
ribavirin
amilorid
absenc
either
compound
mutat
frequenc
result
popul
determin
figur
mm
amilorid
mutat
frequenc
wild
type
increas
tabl
e
averag
mutat
frequenc
viral
popul
shown
mean
number
mutat
per
nucleotid
sequenc
statist
analysi
describ
method
statist
signific
differ
wt
mutat
frequenc
mutat
per
nucleotid
p
similarli
viru
also
increas
mutat
frequenc
mutat
per
nucleotid
p
howev
sinc
basal
mutat
frequenc
lower
increas
better
toler
explain
high
viru
titer
observ
figur
next
determin
whether
observ
mutagen
activ
common
wider
rang
amilorid
compound
wild
type
viru
treat
amilorid
deriv
eipa
mia
benzamil
mutat
frequenc
determin
describ
figur
mutat
frequenc
wild
type
increas
basal
mutat
per
nucleotid
eipa
p
mia
although
tendenc
toward
increas
observ
benzamil
mutat
per
nucleotid
statist
signific
differ
establish
p
furthermor
treatment
eipa
also
increas
mutat
frequenc
mutat
per
nucleotid
p
correl
higher
titer
compar
wild
type
viru
examin
whether
amilorid
treatment
bias
mutat
profil
toward
specif
substitut
common
base
analog
rna
mutagen
untreat
popul
transit
mutat
atog
ttoc
utoc
rna
genom
common
figur
treatment
popul
ribavirin
bias
mutat
profil
result
accumul
gtoa
ctot
ctou
rna
transit
mutat
hand
treatment
amilorid
increas
bia
natur
mutat
profil
taken
togeth
result
provid
first
evid
mutagen
activ
amilorid
compound
suggest
resist
effect
increas
rdrp
fidel
lower
basal
mutat
frequenc
anoth
high
fidel
rdrp
variant
polioviru
also
resist
mutagen
effect
amilorid
variant
polioviru
anoth
higher
fidel
rdrp
variant
whose
fidel
alter
determin
map
differ
region
rdrp
figur
previou
studi
show
resist
ribavirin
azc
fu
replic
similar
kinet
wild
type
polioviru
onestep
growth
curv
northern
blot
analysi
gener
viru
popul
lower
basal
mutat
frequenc
present
higher
fidel
phenotyp
biochem
incorpor
assay
provid
uniqu
opportun
determin
whether
amilorid
exert
mutagen
activ
differ
viru
differ
fidel
increas
mutat
wild
type
poliovirus
treat
amilorid
rel
mutat
frequenc
determin
figur
basal
mutat
frequenc
wild
type
polioviru
mutat
per
nucleotid
sequenc
increas
mutat
per
nucleotid
p
upon
amilorid
treatment
high
fidel
popul
basal
mutat
frequenc
mutat
per
nucleotid
increas
mutat
per
nucleotid
p
amilorid
remain
significantli
lower
wild
type
viru
p
order
determin
whether
lower
basal
mutat
frequenc
correl
resist
amilorid
treat
untreat
popul
titrat
figur
higher
percentag
virus
popul
surviv
amilorid
treatment
compar
wild
type
polioviru
popul
p
result
therefor
confirm
two
differ
high
fidel
rdrp
increas
fidel
lower
mutat
frequenc
confer
resist
amilorid
anoth
polymeras
variant
resist
amilorid
mutagen
activ
differ
mechan
along
harrison
et
al
isol
second
rdrp
variant
screen
amilorid
resist
contrast
screen
rna
mutagen
resist
fail
isol
alongsid
hypothes
either
resist
anoth
amiloridemedi
antivir
effect
inhibit
rna
synthesi
eg
resist
amilorid
mutagen
activ
differ
mechan
wild
type
viru
stock
prepar
cdna
infecti
clone
viru
studi
perform
parallel
wild
type
similar
resist
wild
type
concentr
amilorid
test
figur
one
stepgrowth
studi
perform
absenc
amilorid
show
produc
viru
kinet
similar
wild
type
viru
figur
likewis
northern
blot
analysi
kinet
studi
reveal
produc
higher
level
rna
absenc
amilorid
figur
howev
although
one
step
growth
analysi
grown
presenc
amilorid
also
reveal
signific
differ
viru
titer
compar
wild
type
figur
northern
blot
analysi
rna
synthes
hour
infect
reveal
inhibitori
effect
amilorid
dramat
wild
type
figur
final
examin
potenti
effect
mutat
rdrp
fidel
infect
perform
presenc
ribavirin
amilorid
eipa
mocktreat
mutat
frequenc
determin
popul
unlik
mutat
frequenc
suggest
higher
fidel
compar
wild
type
figur
rather
present
significantli
higher
mutat
frequenc
mutat
per
nucleotid
p
suggest
variant
encod
lower
fidel
polymeras
inde
treatment
mm
ribavirin
increas
mutat
frequenc
mutat
per
nucleotid
significantli
higher
wild
type
p
figur
accord
lower
fidel
polymeras
confirm
lower
fidel
phenotyp
confer
mutat
vitro
biochem
assay
examin
rel
level
misincorpor
purifi
enzym
perform
shown
figur
rdrp
incorpor
gmp
time
wild
type
rdrp
consist
mutat
decreas
rdrp
fidel
tabl
unexpectedli
treat
either
amilorid
eipa
figur
popul
undergo
signific
increas
mutat
frequenc
mutat
per
nucleotid
p
p
respect
suggest
polymeras
complet
unaffect
mechan
amilorid
increas
mutat
wild
type
virus
henc
resist
mutagen
activ
amilorid
increas
rdrp
fidel
partial
resist
rna
replic
inhibit
mutagen
effect
entir
result
argu
increas
mutat
frequenc
previous
unknown
antivir
mechan
amilorid
compound
rel
contribut
rna
synthesi
inhibit
rna
mutagenesi
unclear
examin
rel
contribut
mutagenesi
overal
antivir
effect
determin
mutat
frequenc
wild
type
viru
popul
treat
increas
concentr
ribavirin
amilorid
data
use
determin
fold
increas
mutat
frequenc
wild
type
viru
increas
concentr
drug
compar
untreat
control
inde
ribavirin
treatment
show
dosedepend
increas
mutat
frequenc
figur
dash
line
right
yaxi
correl
decreas
viru
titer
solid
line
left
yaxi
data
agre
previou
work
show
mutagenesi
princip
antivir
mechan
ribavirin
tissu
cultur
contrast
treatment
increas
concentr
amilorid
least
mm
produc
correspond
increas
mutat
frequenc
figur
dash
line
although
decreas
viru
yield
dosedepend
solid
line
northern
blot
analysi
rna
synthesi
differ
amilorid
concentr
reveal
dose
depend
effect
rna
inhibit
figur
result
suggest
replic
inhibit
princip
caus
dosedepend
drop
viru
titer
mutagen
effect
amilorid
result
indirect
doseindepend
effect
polymeras
increas
intracellular
ion
concentr
mg
mn
may
account
mutagen
activ
amilorid
compound
dose
depend
decreas
viral
titer
figur
attribut
inhibit
rna
synthesi
propos
result
direct
interact
amilorid
rdrp
given
dose
depend
mutat
frequenc
observ
amilorid
hypothes
mutagen
effect
indirect
result
effect
amilorid
cellular
environ
inde
previou
studi
shown
amilorid
treatment
alter
intracellular
concentr
free
na
ca
mg
turn
alter
equilibrium
level
ion
includ
mn
mg
mn
interest
candid
sinc
cofactor
essenti
incorpor
activ
polymeras
viral
rdrp
cell
cultur
condit
confirm
addit
commonli
studi
effect
na
mg
level
also
significantli
perturb
cell
treat
amilorid
p
figur
examin
potenti
role
alter
intracellular
cation
concentr
observ
mutagen
activ
wild
type
virus
grown
cell
media
supplement
high
concentr
either
nacl
cacl
mgcl
mncl
result
mutat
frequenc
determin
growth
three
virus
either
nacl
cacl
signific
effect
mutat
frequenc
figur
increas
intracellular
mg
mn
concentr
hand
result
signific
increas
mutat
frequenc
wild
type
mg
p
mn
figur
p
mg
p
mn
figur
virus
frequenc
significantli
lower
wild
type
would
expect
higher
fidel
variant
contrast
mutat
frequenc
remain
unchang
p
mg
p
mn
figur
importantli
onestep
growth
analysi
viru
grown
presenc
concentr
mgcl
confirm
replic
affect
figur
given
similar
sensit
resist
profil
variant
amilorid
treat
popul
result
support
notion
amilorid
induc
mutagenesi
result
chang
intracellular
concentr
essenti
dival
cation
cofactor
gather
support
link
amilorid
mutagenesi
mg
mn
concentr
wild
type
viru
serial
passag
presenc
either
compound
rdrp
region
passag
viru
popul
sequenc
interv
indic
figur
interestingli
wild
type
viru
grown
presenc
mncl
acquir
passag
fix
passag
onward
high
fidel
mutat
select
rna
mutagen
figur
amilorid
passag
similarli
passag
wild
type
viru
mgcl
select
high
fidel
fix
popul
passag
report
identifi
previous
undescrib
mutagen
effect
amilorid
treatment
polioviru
figur
confirm
amilorid
inhibit
rna
synthesi
coxsacki
viru
figur
rel
contribut
two
activ
observ
antivir
effect
amilorid
compound
dose
depend
inhibit
rna
synthesi
figur
correl
dose
depend
reduct
wild
type
viru
titer
figur
suggest
princip
antivir
activ
amilorid
may
reflect
direct
interact
amilorid
rdrp
perhap
block
nucleotid
entri
tunnel
catalyt
site
suggest
harrison
et
al
detail
vitro
biochem
vitro
replic
assay
help
determin
natur
interact
molecular
basi
amilorid
induc
mutagenesi
lack
dose
depend
observ
mutagen
effect
higher
concentr
amilorid
figur
typic
observ
rna
mutagen
ribavirin
figur
led
us
seek
indirect
mechan
amilorid
induc
mutagenesi
amilorid
inhibit
epitheli
na
channel
na
h
ion
antiport
less
character
ion
exchang
na
ca
na
mg
could
turn
affect
equilibrium
ion
mn
inde
experiment
condit
observ
signific
alter
intracellular
mg
concentr
although
mm
amilorid
treatment
necessari
detect
limit
figur
sinc
mg
mn
essenti
cofactor
polymeras
activ
nucleotid
insert
explor
potenti
link
amilorid
treatment
mg
mn
level
mutat
frequenc
inde
found
increas
intracellular
mg
mn
correl
increas
viru
mutat
frequenc
figur
whether
amilorid
inhibit
mg
andor
mn
transport
directli
yet
identifi
eukaryot
indirectli
effect
na
channel
exchang
difficult
determin
studi
channel
blocker
differ
structur
may
help
pinpoint
mechan
although
redund
channel
may
mask
effect
nevertheless
mutagenesi
resist
profil
amilorideresist
variant
support
link
cation
concentr
amilorid
mutagen
effect
higher
fidel
rdrp
variant
gener
viru
popul
lower
basal
mutat
frequenc
wild
type
popul
result
viru
popul
although
impervi
effect
mutagen
better
toler
moder
increas
mutat
frequenc
would
otherwis
lethal
mutagen
wild
type
popul
accordingli
mutat
frequenc
increas
follow
ribavirin
treatment
amilorid
treatment
treatment
high
concentr
mg
mn
case
frequenc
significantli
lower
wild
type
popul
treatment
unlik
variant
sole
resist
mutagen
antivir
activ
sinc
rna
synthesi
inhibit
amilorid
wild
type
viru
figur
perhap
reason
passag
wild
type
viru
mg
mn
mimic
mutagen
rdrp
inhibitori
activ
amilorid
result
select
high
fidel
variant
figur
variant
seem
resist
amilorid
front
rna
synthesi
less
inhibit
figur
mutat
frequenc
unchang
figur
whether
dual
mechan
resist
amilorid
antivir
activ
tightli
coupl
coincident
remain
determin
nevertheless
similar
lack
mutagen
effect
mg
mn
treatment
figur
provid
support
role
dival
cation
amilorideinduc
mutagenesi
howev
seem
come
cost
decreas
overal
rdrp
fidel
evidenc
hypersensit
nucleosid
mutagen
ribavirin
vitro
biochem
data
figur
interestingli
low
fidel
variant
polioviru
fmdv
also
map
loop
domain
interact
activ
site
coordin
one
two
dival
cation
cofactor
incom
nucleotid
occur
alter
domain
may
alter
rdrp
depend
rel
avail
mg
cofactor
therebi
result
lower
fidel
mg
concentrationinsensit
rdrp
may
chang
prefer
mg
mn
polioviru
posit
variant
shown
lower
fidel
rdrp
vitro
posit
variant
fmdv
also
present
higher
mutat
frequenc
earlier
studi
posit
polioviru
variant
found
depend
mn
growth
biochem
assay
shown
polioviru
rdrp
activ
presenc
mn
result
higher
mutat
frequenc
mn
depend
may
explain
higher
basal
mutat
frequenc
rel
wild
type
viru
use
rna
mutagen
extinguish
viral
popul
hypermut
promis
antivir
approach
lower
fidel
variant
could
readili
identifi
weakli
mutagen
base
analog
could
later
improv
higher
fidel
variant
would
help
test
efficaci
strongest
mutagen
nucleosid
nonnucleosid
structur
sinc
descript
lethal
mutagenesi
use
base
analog
specul
whether
compound
alter
mutat
frequenc
direct
indirect
action
rdrp
import
note
mutagen
activ
amilorid
observ
studi
signific
observ
nucleosid
rna
mutagen
rais
twosid
question
activ
amilorid
strong
enough
lethal
mutagen
viru
popul
prolong
exposur
would
moder
increas
mutat
frequenc
help
viru
rapidli
evolv
escap
immun
respons
experiment
condit
mutagen
effect
strong
enough
forc
viru
develop
two
mechan
resist
suggest
mutagen
activ
alon
suffici
detriment
viru
whether
antivir
mutagen
effect
observ
occur
physiolog
intracellular
amilorid
concentr
human
yet
known
may
affect
fidel
cellular
rna
polymeras
remain
studi
nevertheless
work
uncov
new
target
drug
discoveri
compound
induc
revers
alter
intracellular
concentr
essenti
cation
cofactor
viral
rdrp
result
encourag
screen
compound
librari
new
molecul
direct
interact
rdrp
indirect
effect
intracellular
environ
may
alter
mutat
frequenc
rna
virus
modul
polymeras
fidel
final
studi
identifi
two
new
rdrp
fidel
variant
date
posit
variant
polioviru
shown
exhibit
increas
rdrp
fidel
despit
similar
rdrp
structur
map
distant
region
polymeras
figur
previou
work
current
find
higher
fidel
lower
fidel
along
descript
lower
fidel
rdrp
polioviru
foot
mouth
diseas
viru
suggest
intrins
fidel
rdrp
defin
multipl
residu
full
extent
fidel
network
whether
translat
across
rdrp
differ
viru
famili
yet
determin
addit
util
studi
current
report
rdrp
variant
valuabl
tool
studi
viral
evolut
adapt
rna
viru
popul
vivo
interest
determin
viru
popul
increas
decreas
genet
divers
behav
context
coxsacki
viru
infect
hela
young
vero
cell
maintain
dmem
medium
newborn
calf
serum
plasmid
bear
cdna
coxsacki
viru
nanci
strain
kind
gift
f
van
kuppeveld
radboud
univers
nijmegen
netherland
plasmid
contain
polioviru
cdna
previous
describ
follow
compound
obtain
sigma
aldrich
ribavirin
studi
perform
viru
stock
wild
type
gener
cdna
infecti
clone
variant
construct
use
quikchang
xl
site
direct
mutagenesi
kit
stratagen
infecti
cdna
three
infecti
cdna
clone
variant
obtain
sequenc
use
gener
three
independ
viru
stock
three
viru
stock
wild
type
viru
also
prepar
manner
three
stock
serv
one
three
triplic
sampl
replic
studi
rna
mutagen
amilorid
compound
sensit
assay
mutat
frequenc
data
viru
popul
gener
clone
variant
use
throughout
studi
basal
mutat
frequenc
determin
independ
gener
sampl
variant
statist
signific
differ
mutat
frequenc
found
cdna
plasmid
linear
sal
polioviru
cdna
plasmid
eco
ri
linear
plasmid
purifi
qiagen
pcr
purif
kit
mg
linear
plasmid
vitro
transcrib
use
rna
polymeras
fermenta
mg
transcript
electropor
vero
cell
wash
twice
pb
wo
ca
mg
resuspend
pb
wo
ca
mg
cellsml
electropor
condit
follow
mm
cuvett
mf
v
maximum
resist
exponenti
decay
biorad
genepuls
xcell
electropor
cell
recov
dmem
ml
viru
stock
use
infect
vero
cell
flask
produc
viru
ml
viru
use
infect
vero
cell
nc
flask
produc
viru
passag
viru
harvest
total
cytopath
effect
cpe
one
freezethaw
cycl
clarifi
spin
k
rpm
minut
tenfold
serial
dilut
viru
prepar
roundbottom
plate
pb
dilut
perform
octupl
ml
dilut
transfer
vero
cell
plate
ml
dmem
day
live
cell
monolay
color
crystal
violet
tcid
valu
determin
reed
muensch
method
plaqu
assay
hela
cell
seed
plate
viru
prepar
serial
dilut
pb
cell
wash
twice
pb
infect
ml
dilut
minut
semisolid
overlay
compris
dmem
medium
wv
avicel
fmc
biopolym
ad
day
infect
cell
wash
stain
crystal
violet
plaqu
enumer
hela
cell
monolay
pretreat
mm
ribavirin
mm
mm
mgcl
mm
mncl
hour
infect
tcid
blind
serial
passag
perform
fresh
mutagentr
hela
cell
monolay
ml
viruscontain
supernat
indic
passag
interv
viral
rna
extract
purifi
virion
trizol
reagent
invitrogen
rtpcr
perform
titan
onestep
roch
pcr
product
sequenc
identifi
consensu
sequenc
chang
within
rdrp
region
nucleotid
hela
cell
monolay
plate
pretreat
hour
ribavirin
azc
fu
nacl
cacl
mgcl
mncl
hour
amilorid
compound
differ
concentr
compound
indic
chose
verifi
concentr
compound
toxic
cell
hour
period
amilorid
compound
chose
confirm
concentr
correspond
viru
inhibitori
concentr
ic
valu
toxic
cell
determin
harrison
et
al
cell
infect
moi
passag
viru
hour
postinfect
viru
harvest
one
freezethaw
cycl
viru
titer
tcid
plaqu
assay
determin
replic
studi
hela
cell
either
pretreat
mm
amilorid
mock
treat
infect
moi
onestep
growth
kinet
transfect
cell
frozen
differ
time
point
infect
later
titer
tcid
assay
northern
blot
analysi
total
rna
infect
cell
extract
trizol
reagent
invitrogen
purifi
mg
total
rna
use
per
sampl
measur
nanodrop
gel
transfer
onto
nitrocellulos
membran
whatman
turboblott
supercharg
nylon
membran
kit
hybrid
overnight
dctpa
p
label
dna
probe
correspond
bp
rdrp
visual
storm
phosphorimag
analyz
imagequ
total
cpe
viral
rna
supernat
extract
rtpcr
amplifi
use
primer
set
viru
polioviru
result
pcr
product
purifi
column
nucleospin
machereynagel
topota
clone
invitrogen
bluewhit
screen
use
singl
coloni
transform
posit
clone
sequenc
gatc
biotech
sequenc
data
analyz
use
lasergen
softwar
packag
dnastar
inc
statist
purpos
retain
sequenc
data
region
everi
clone
repres
nucleotid
nucleotid
pv
number
mutat
per
nucleotid
sequenc
determin
use
total
mutat
identifi
per
popul
total
number
nucleotid
sequenc
popul
multipli
popul
clone
sequenc
repres
nucleotid
per
sampl
see
tabl
mutat
recur
popul
count
howev
occur
two
instanc
one
singl
repetit
suffici
chang
mutat
frequenc
valu
statist
confluent
layer
hela
cell
treat
mm
amilorid
hour
incub
pb
contain
mm
ethylen
glycolbi
baminoethyl
ether
n
n
n
ntetraacet
acid
egta
min
chelat
ca
lysi
ratiometr
magnesium
indic
invitrogen
ad
final
concentr
mm
ml
sampl
fluoresc
measur
use
quantamast
spectrofluoromet
pti
use
cm
path
length
quartz
cuvett
thermost
excit
scan
perform
nm
nm
step
use
nm
bandwidth
emiss
monitor
nm
nm
bandwidth
continu
record
fluoresc
intens
nm
nm
transform
wavelength
ratio
one
step
growth
curv
mutagen
treatment
assay
mg
concentr
assay
twotail
pair
student
test
use
determin
signific
confid
interv
mutat
frequenc
x
test
twotail
mann
whitney
u
test
perform
x
test
compar
total
number
mutat
popul
total
nucleotid
sequenc
mann
whitney
test
compar
rank
score
number
mutat
found
individu
clone
group
popul
case
mann
whitney
test
gave
conserv
p
valu
indic
statist
perform
use
prism
softwar
graphpad
inc
rna
oligonucleotid
dharmacon
research
inc
p
atp
cimmol
mp
biomed
polynucleotid
kinas
usb
atp
gtp
ge
healthcar
reagent
highest
grade
avail
sigma
fisher
vwr
rna
oligonucleotid
purifi
denatur
page
endlabel
use
p
atp
polynucleotid
kinas
describ
previous
concentr
determin
measur
absorb
nm
use
nanodrop
spectrophotomet
use
appropri
calcul
extinct
coeffici
express
construct
wild
type
rdrp
creat
use
standard
recombin
dna
protocol
dna
sequenc
amplifi
use
appropri
cdna
templat
forward
revers
primer
employ
amplif
select
base
presenc
uniqu
restrict
site
suitabl
clone
gene
rdrp
psumo
express
plasmid
e
coli
rosetta
cell
tansform
appropri
plasmid
cell
use
produc
inoculum
largescal
growth
gene
express
induc
exponenti
growth
addit
isopropylbdthiogalactopyranosid
use
autoinduct
induc
cell
lyse
appropri
buffer
enzym
purifi
appar
homogen
use
standard
column
chromatographi
resin
protocol
reaction
perform
plabel
primer
extens
assay
mm
rdrp
mix
mm
p
primertempl
substrat
mm
hepe
ph
mm
mgcl
mm
zncl
mm
reaction
initi
addit
atp
gtp
mm
mm
hepe
ph
mm
mgcl
mm
zncl
mm
mm
nacl
reaction
quench
variou
time
addit
quench
buffer
mm
edta
formamid
bromphenol
blue
xylen
cyanol
rdrp
dilut
immedi
prior
use
mm
hepe
ph
glycerol
mm
volum
enzym
ad
reaction
alway
less
equal
onetenth
total
volum
product
resolv
denatur
page
stoppedflow
fluoresc
assay
presteadi
state
stoppedflow
fluoresc
experi
perform
use
model
stoppedflow
apparatu
kintek
corp
austin
tx
equip
waterbath
reaction
perform
mm
mix
mm
primertempl
substrat
contain
ribonucleosid
side
templat
base
mm
hepe
ph
mm
mgcl
mm
zncl
mm
reaction
initi
addit
mm
atp
mm
hepe
ph
mm
mgcl
mm
zncl
mm
mm
nacl
mix
reactant
concentr
reduc
fluoresc
emiss
monitor
use
nm
cuton
filter
model
chroma
technolog
corp
rockingham
vt
excit
wavelength
use
nm
experi
least
four
fluoresc
trace
averag
rel
fluoresc
plot
function
time
fit
singl
exponenti
equat
fae
kob
zc
f
rel
fluoresc
intens
kob
observ
rate
constant
nucleotid
incorpor
time
c
offset
quench
reaction
mixtur
heat
min
prior
load
ml
denatur
polyacrylamid
gel
contain
tbe
urea
electrophoresi
perform
tbe
watt
gel
visual
use
phosphorimag
quantifi
use
imagequ
softwar
molecular
dynam
data
fit
nonlinear
regress
use
program
kaleidagraph
synergi
softwar
read
pa
figur
amilorid
treatment
cell
increas
free
intracellular
mg
concentr
hela
cell
treat
hour
mm
without
amilorid
wash
lyse
increas
intracellular
mg
concentr
determin
chang
ratio
emiss
signal
nm
use
indic
mean
valu
sem
shown
p
n
found
mb
ep
figur
local
fidel
alter
mutat
picornaviru
rdrp
crystal
structur
rdrp
shown
color
format
progress
n
terminu
blue
c
terminu
red
posit
shown
increas
fidel
polioviru
rdrp
posit
decreas
fidel
rdrp
posit
increas
fidel
rdrp
indic
illustr
ball
structur
locat
catalyt
site
picornaviru
rdrp
also
indic
repres
line
structur
